Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options

Rhea-AI Filing Summary

Viking Therapeutics reported that Chief Medical Officer Hubert C. Chen received a grant of stock options. The award covers 190,000 options to buy common stock at an exercise price of $31.27 per share, expiring on June 1, 2036. According to the vesting terms, 25% of the options vested immediately on the grant date, with an additional 25% vesting on each one-year anniversary over the next three years. Following this compensation-related grant, Chen holds 190,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chen Hubert C

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	190,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 190,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 190,000 options Exercise price: $31.27 per share Expiration date: June 1, 2036 +3 more

6 metrics

Stock options granted 190,000 options Grant to Chief Medical Officer on June 1, 2026

Exercise price $31.27 per share Strike price for granted stock options

Expiration date June 1, 2036 Option expiration for the 190,000 options

Immediate vesting portion 25% of options Vested on the grant date per vesting schedule

Annual vesting installments 25% per year Each one-year anniversary over the next three years

Options held after grant 190,000 options Total stock options directly held post-transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 31.2700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"shares subject to the option vested immediately, and 25% ... will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chen Hubert C

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.27	06/01/2026		A		190,000		(1)	06/01/2036	Common Stock	190,000	$0	190,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vested immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years.

	/s/ Michael Morneau, as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Viking Therapeutics (VKTX) report for Hubert C. Chen?

Viking Therapeutics reported a compensation-related grant of 190,000 stock options to Chief Medical Officer Hubert C. Chen. These options give the right to buy common shares at a fixed exercise price and are disclosed as an acquisition on a Form 4.

What are the key terms of Hubert C. Chen’s 190,000 Viking Therapeutics (VKTX) stock options?

The grant covers 190,000 stock options with an exercise price of $31.27 per share and an expiration date of June 1, 2036. The options are tied to Viking Therapeutics’ common stock as the underlying security.

How do Hubert C. Chen’s Viking Therapeutics (VKTX) options vest?

The vesting schedule provides that 25% of the options vested immediately on the grant date. The remaining 75% will vest in three equal 25% installments on each one-year anniversary of the grant date over the next three years.

Is Hubert C. Chen’s Form 4 transaction in VKTX an open-market purchase or a grant?

The Form 4 shows a grant or award acquisition of derivative securities, not an open-market purchase. The transaction code is “A,” indicating a grant of stock options as compensation rather than buying existing shares in the market.

How many Viking Therapeutics (VKTX) options does Hubert C. Chen hold after this grant?

After the reported transaction, Hubert C. Chen holds 190,000 stock options directly. This total reflects the full amount of the newly granted options as shown in the post-transaction holdings field on the Form 4.